



Economic and Social Council

Distr.: General
19 December 2023

Original: English

Commission on Narcotic Drugs

Sixty-seventh session

Vienna, 14–22 March 2024

Annotated provisional agenda

Provisional agenda

1. Election of officers.
2. Adoption of the agenda and other organizational matters.

High-level segment

3. High-level segment:
 - (a) Opening of the high-level segment;
 - (b) General debate of the high-level segment;
 - (c) Interactive, multi-stakeholder round tables of the high-level segment:
 - (i) Taking stock: work undertaken since 2019;
 - (ii) The way forward: the road to 2029;
 - (d) Closure of the high-level segment.

Operational segment

4. Strategic management, budgetary and administrative questions:
 - (a) Work of the standing open-ended intergovernmental working group on improving the governance and financial situation of the United Nations Office on Drugs and Crime;
 - (b) Directives on policy and budgetary issues for the drug programme of the United Nations Office on Drugs and Crime;
 - (c) Working methods of the Commission;
 - (d) Staff composition of the United Nations Office on Drugs and Crime and other related matters.

Normative segment

5. Implementation of the international drug control treaties:
 - (a) Changes in the scope of control of substances;



- (b) Challenges and future work of the Commission on Narcotic Drugs and the World Health Organization in the review of substances for possible scheduling recommendations;
 - (c) International Narcotics Control Board;
 - (d) International cooperation to ensure the availability of narcotic drugs and psychotropic substances for medical and scientific purposes while preventing their diversion;
 - (e) Other matters arising from the international drug control treaties.
6. Follow-up to the implementation at the national, regional and international levels of all commitments, as reflected in the Ministerial Declaration of 2019, to address and counter the world drug problem.
 7. Inter-agency cooperation and coordination of efforts in addressing and countering the world drug problem.
 8. Recommendations of the subsidiary bodies of the Commission.
 9. Contributions by the Commission to the work of the Economic and Social Council, in line with General Assembly resolutions 75/290 A and 75/290 B, including follow-up to and review and implementation of the 2030 Agenda for Sustainable Development.
- ***
10. Provisional agenda for the sixty-eighth session of the Commission.
 11. Other business.
 12. Adoption of the report of the Commission on its sixty-seventh session.

Annotations

1. Election of officers

In section I of its resolution 1999/30, the Economic and Social Council decided that, with effect from the year 2000, the Commission on Narcotic Drugs should, at the end of each session, elect its Bureau for the subsequent session and should encourage it to play an active role in the preparations for the regular as well as the intersessional meetings of the Commission, so as to enable the Commission to provide continuous and effective policy guidance to the drug programme of the United Nations Office on Drugs and Crime (UNODC).

In accordance with section I of Economic and Social Council resolution 1999/30 and rule 15 of the rules of procedure of the functional commissions of the Council, the Commission, at the end of its reconvened sixty-sixth session, on 8 December 2023, opened its sixty-seventh session for the sole purpose of electing its Bureau for that session. At that meeting, the Commission elected the members of the Bureau.

In view of the rotation of offices based on regional distribution, the officers of the Commission at its sixty-seventh session and their respective regional groups are as follows:

<i>Office</i>	<i>Regional group</i>	<i>Officer</i>
Chair	African States	Philbert Abaka Johnson (Ghana)
First Vice-Chair	Asia-Pacific States	Asad Alam Siam (Bangladesh)
Second Vice-Chair	Eastern European States	Barbara Zvokelj (Slovenia)

<i>Office</i>	<i>Regional group</i>	<i>Officer</i>
Third Vice-Chair	Western European and other States	Natasha Meli Daudey (Malta)
Rapporteur	Latin American and Caribbean States	Fabio Esteban Pedraza Torres (Colombia)

In accordance with Economic and Social Council resolution 1991/39 and established practice, a group composed of the Chairs of the five regional groups, the Chair of the Group of 77 and China and the representative of or observer for the State holding the Presidency of the European Union assists the Chair of the Commission in dealing with organizational matters. That group, together with the officers, constitutes the extended Bureau foreseen in Council resolution 1991/39.

2. Adoption of the agenda and other organizational matters

In section I of its resolution 1999/30, the Economic and Social Council decided that the normative functions of the Commission should be made distinct from its role as the governing body of the drug programme of UNODC and that, to that end, the agenda of the Commission should be structured in two distinct segments, as follows:

(a) A normative segment, during which the Commission would discharge its treaty-based and normative functions, including mandates received from the General Assembly and the Council, and deal with emerging drug control issues;

(b) An operational segment, during which the Commission would exercise its role as the governing body of the drug programme of UNODC and consider issues related to the provision of policy guidance to the Office.

The provisional agenda for the sixty-seventh session of the Commission has been structured to comply with Economic and Social Council resolution 1999/30.

Rule 7 of the rules of procedure of the functional commissions of the Economic and Social Council provides that the Commission shall, at the beginning of each session, adopt the agenda for that session on the basis of the provisional agenda.

In its decision 2023/318, the Economic and Social Council took note of the report of the Commission on its sixty-sixth session and approved the provisional agenda for the sixty-seventh session of the Commission.

At its reconvened sixty-sixth session, held on 7 and 8 December 2023, the Commission decided that its sixty-seventh session would be held from 14 to 22 March 2024, including a high-level segment to be held on 14 and 15 March 2024. The Commission also decided that it would hold its reconvened sixty-seventh session on 5 and 6 December 2024.

In accordance with Commission decision 55/1, the firm deadline for the submission of draft resolutions is one month prior to the commencement of the session. The Commission decided that the deadline would be set for Thursday, 15 February 2024, at noon.

Following the adoption of the agenda, the Commission may wish to establish a timetable and agree on the organization of work for the sixty-seventh session. The proposed organization of work is contained in the annex to the present document.

Documentation

Annotated provisional agenda ([E/CN.7/2024/1](#))

High-level segment**3. High-level segment****(a) Opening of the high-level segment**

In the Ministerial Declaration on Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem,¹ adopted during the ministerial segment of its sixty-second session, in March 2019, Member States resolved to review in the Commission on Narcotic Drugs in 2029 progress in implementing all international drug policy commitments, with a midterm review in the Commission in 2024.

In its resolution 66/1, the Commission decided to convene a high-level segment to take stock of the implementation of all international drug policy commitments and outline the way forward to 2029, in line with the Ministerial Declaration of 2019, to be held during its sixty-seventh session, in Vienna in 2024, for a period of two days, in addition to the five days usually scheduled for the regular part of the session of the Commission, held in the first half of the year.

Also in its resolution 66/1, the Commission decided that the high-level segment would consist of a general debate and two interactive, multi-stakeholder roundtables held in parallel with the general debate, and that the high-level segment would be organized in accordance with the rules of procedure of the functional commissions of the Economic and Social Council. It also decided on participation in the round tables, chairing arrangements and composition of the panels.

In its resolution 66/1, the Commission further decided to work in good faith towards adopting a concise, action-oriented document at the opening of the high-level segment of its sixty-seventh session, which would be negotiated during the intersessional period preceding the regular sixty-seventh session of the Commission, focused exclusively on taking stock of the implementation of all existing international drug policy commitments between 2019 and 2023, and indicating the work to be done to accelerate the implementation in the period from 2024 until 2029 of all those existing commitments.

(b) General debate of the high-level segment

In its resolution 66/1, the Commission decided that following the format of the general debates conducted during the high-level segments of the fifty-second, fifty-seventh, and sixty-second sessions of the Commission, held in 2009, 2014 and 2019, the meetings of the general debate would be open to all States Members of the United Nations. Representatives of intergovernmental organizations and non-governmental organizations in consultative status with the Economic and Social Council could participate, in accordance with rules 74 to 76 of the rules of procedure of the functional commissions of the Council.

At the reconvened sixty-sixth session of the Commission, the organizational arrangements for the general debate were brought to the attention of the Commission in the form of a conference room paper (E/CN.7/2023/CRP.17), which will be made available in document [E/CN.7/2024/5](#) at the sixty-seventh session.

At the opening of the sixty-seventh session, the Chair reminded delegations about the “Pledge4Action” initiative, which called upon Member States to pledge substantive and financial action to enhance the implementation of the joint international drug policy commitments. More information on the initiative can be found on the web page for the midterm review of 2024.²

¹ See *Official Records of the Economic and Social Council, 2019, Supplement No. 8 (E/2019/28)*, chap. I, sect. B.

² www.unodc.org/unodc/en/commissions/CND/session/67_Session_2024/review.html.

(c) Interactive, multi-stakeholder round tables of the high-level segment**(i) Taking stock: work undertaken since 2019****(ii) The way forward: the road to 2029**

At the reconvened sixty-sixth session of the Commission, the organizational arrangements for the round-table discussions were brought to the attention of the Commission in the form of a conference room paper (E/CN.7/2023/CRP.17), which will be made available in document [E/CN.7/2024/5](#) at the sixty-seventh session.

(d) Closure of the high-level segment

In accordance with Commission resolution 66/1 and in line with the rules of procedure of the functional commissions of the Economic and Social Council, in particular rule 35, a non-negotiated summary of the salient points raised during the round tables is to be prepared by the co-chairs of each round table and will be presented to the plenary.

The high-level segment will be declared closed following the conclusion by the Commission of its consideration of item 3.

Documentation

Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem³

Joint Ministerial Statement of the 2014 high-level review by the Commission on Narcotic Drugs of the implementation by Member States of the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem⁴

Outcome document of the thirtieth special session of the General Assembly, entitled “Our joint commitment to effectively addressing and countering the world drug problem” (General Assembly resolution S-30/1, annex)

Ministerial Declaration on Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem⁵

Note by the Secretariat on the organization of the high-level segment to take stock of the implementation of all international drug policy commitments and outline the way forward to 2029, in line with the Ministerial Declaration of 2019 ([E/CN.7/2024/5](#))

Conference room paper containing the Chair’s summary on the thematic discussions on the implementation of all international drug policy commitments, following up to the Ministerial Declaration of 2019 (23–25 October and 4–6 December 2023) (E/CN.7/2024/CRP.1)

Conference room paper containing a note by the Secretariat on the implementation of all international drug policy commitments, following up to the Ministerial Declaration of 2019 (E/CN.7/2024/CRP.2)

Conference room paper prepared by the Secretariat on background documentation for the interactive, multi-stakeholder round tables of the high-level segment (E/CN.7/2024/CRP.4)

³ See *Official Records of the Economic and Social Council, 2009, Supplement No. 8 (E/2009/28)*, chap. I, sect. C.

⁴ *Ibid.*, 2014, *Supplement No. 8 (E/2014/28)*, chap. I, sect. C.

⁵ *Ibid.*, 2019, *Supplement No. 8 (E/2019/28)*, chap. I, sect. B.

Operational segment

4. **Strategic management, budgetary and administrative questions**
 - (a) **Work of the standing open-ended intergovernmental working group on improving the governance and financial situation of the United Nations Office on Drugs and Crime**
 - (b) **Directives on policy and budgetary issues for the drug programme of the United Nations Office on Drugs and Crime**
 - (c) **Working methods of the Commission**
 - (d) **Staff composition of the United Nations Office on Drugs and Crime and other related matters**

For its consideration of item 4, the Commission will have before it the report of the Executive Director on the activities of UNODC ([E/CN.7/2024/2-E/CN.15/2024/2](#)), which contains information on the strategic orientation of UNODC and progress made by UNODC in implementing its mandates with regard to the five thematic areas outlined in the UNODC Strategy 2021–2025: addressing and countering the world drug problem; preventing and countering organized crime; preventing and countering corruption and economic crime; preventing and countering terrorism; and crime prevention and criminal justice. The report also provides information on the activities undertaken with regard to strengthening UNODC (inter alia, measures relating to United Nations reform and results-based management; partnerships; research, evidence-based policy and data analysis; communication; resource mobilization; cross-cutting commitments; and organizational culture) and a number of recommendations for consideration by the Commission.

At its sixty-seventh session, the Commission will have before it a note by the Secretariat on the work of the standing open-ended intergovernmental working group on improving the governance and financial situation of UNODC ([E/CN.7/2024/3-E/CN.15/2024/3](#)).

At its reconvened sixty-sixth session, the Commission adopted resolution 66/5, entitled “Budget for the biennium 2024–2025 for the Fund of the United Nations International Drug Control Programme”. In that resolution, the Commission, inter alia, noted with concern the financial challenges faced by UNODC owing to the shortfall in general-purpose funding affecting the ability of the Office to effectively uphold core programmatic functions, such as normative work and research. The Commission also noted with concern that despite an increase in special-purpose funding, some challenges remained with regard to the provision by the Office of technical assistance and capacity-building to interested Member States. The Commission further noted the alignment of the proposed budget with the Charter of the United Nations, as well as the contribution by UNODC to the implementation of the 2030 Agenda for Sustainable Development and other relevant transformation agendas agreed by Member States.

At the same session, the Commission considered the report of the Executive Director on the consolidated budget for the biennium 2024–2025 for UNODC ([E/CN.7/2023/13-E/CN.15/2023/17](#)), and a conference room paper prepared by the Secretariat on the draft proposed programme plan for 2025 and programme performance for 2023 for UNODC ([E/CN.7/2023/CRP.15-E/CN.15/2023/CRP.11](#)). The draft proposed programme plan for 2025 and programme performance for 2023 were subsequently transmitted to the Office of Programme Planning, Finance and Budget at United Nations Headquarters.

At its sixty-seventh session, the Commission will have before it a note by the Secretariat on the draft proposed programme plan for 2025 and programme performance for 2023 for UNODC ([E/CN.7/2024/4-E/CN.15/2024/4](#)).

At its reconvened sixty-sixth session, the Commission also considered the report of the Executive Director on gender balance and geographical representation within UNODC ([E/CN.7/2023/12-E/CN.15/2023/16](#)).

At its sixty-seventh session, the Commission may wish to continue discussing the efforts undertaken by UNODC to ensure the recruitment of staff on as wide a geographical basis as possible, in particular in the Professional and higher categories, and to achieve the goal of gender balance.

Documentation

Report of the Executive Director on the activities of the United Nations Office on Drugs and Crime ([E/CN.7/2024/2-E/CN.15/2024/2](#))

Note by the Secretariat on the work of the standing open-ended intergovernmental working group on improving the governance and financial situation of the United Nations Office on Drugs and Crime ([E/CN.7/2024/3-E/CN.15/2024/3](#))

Note by the Secretariat on the draft proposed programme plan for 2025 and programme performance for 2023 ([E/CN.7/2024/4-E/CN.15/2024/4](#))

Normative segment

5. Implementation of the international drug control treaties

Under item 5, the Commission is called upon to carry out its treaty functions under the provisions of various articles of the international drug control treaties.

(a) Changes in the scope of control of substances

The forty-sixth meeting of the Expert Committee on Drug Dependence of the World Health Organization (WHO) was held from 16 to 20 October 2023. At that meeting, the Committee undertook critical reviews of six psychoactive substances, namely, two benzodiazepines, bromazolam and flubromazepam; one synthetic opioid, butonitazene; two stimulants, 3-chloromethcathinone (3-CMC) and dipentylone; and one dissociative-type substance, 2-fluorodeschloroketamine.

Pursuant to article 3, paragraphs 1 and 3, of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol and article 2, paragraphs 1 and 4, of the Convention on Psychotropic Substances of 1971, the Director General of WHO notified the Secretary-General in his communication dated 15 November 2023 of the following recommendations:

1. To be added to Schedule I of the 1961 Convention as amended:
 - (a) butonitazene;
2. To be added to Schedule II of the 1971 Convention:
 - (a) 3-chloromethcathinone (3-CMC);
 - (b) dipentylone;
 - (c) 2-fluorodeschloroketamine;
3. To be added to Schedule IV of the 1971 Convention:
 - (a) bromazolam.

At its sixty-seventh session, the Commission will have before it a note by the Secretariat on changes in the scope of control of substances ([E/CN.7/2024/12](#)), containing relevant extracts from the report on the forty-sixth meeting of the WHO Expert Committee on Drug Dependence, including the Committee's recommendations and the assessments and findings on which those recommendations were based.

The Commission will also have before it a note by the Secretariat on changes in the scope of control of substances under the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 ([E/CN.7/2024/13](#)),

containing information transmitted by the International Narcotics Control Board (INCB) pursuant to article 12, paragraphs 4 and 5, of the 1988 Convention, with regard to the assessments of P-2-P methyl glycidic acid (“BMK glycidic acid”) and its methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl and *tert*-butyl esters. In the same document, the Commission will have before it, for consideration, the Board’s assessment of the ethyl ester of 3,4-MDP-2-P methyl glycidic acid (“PMK ethyl glycidate”) and of six additional esters of 3,4-MDP-2-P methyl glycidic acid for possible inclusion in the tables of the 1988 Convention.

Pursuant to article 12, paragraph 2, of the 1988 Convention, the Government of the United States of America requested, through a letter from the Secretary of State to the Secretary-General dated 5 July 2023, that two fentanyl precursors, namely, 4-piperidone and 1-boc-4-piperidone, be included in the tables of the 1988 Convention. That request was shared with Governments and INCB through a note verbale dated 3 August 2023, in which Governments were invited to communicate their comments concerning the request, together with all supplementary information, by means of two questionnaires that were attached to the note in order to assist the Board in establishing an assessment and the Commission in reaching a decision.

The Commission will have before it a note by the Secretariat on changes in the scope of control of substances under the 1988 Convention ([E/CN.7/2024/14](#)), containing information transmitted by INCB pursuant to article 12, paragraphs 4 and 5, of the 1988 Convention with regard to the assessment of 4-piperidone and 1-boc-4-piperidone for possible inclusion in the tables of the 1988 Convention.

(b) Challenges and future work of the Commission on Narcotic Drugs and the World Health Organization in the review of substances for possible scheduling recommendations

The sub-item entitled “Challenges and future work of the Commission on Narcotic Drugs and the World Health Organization in the review of substances for possible scheduling recommendations” was added to the provisional agenda for the fifty-seventh session of the Commission and maintained on the agendas of the subsequent sessions to assist Member States in applying the existing scheduling procedures contained in the three international drug control conventions. Under the sub-item, the Commission will address the ongoing challenge of identifying and detecting new psychoactive substances.

In the outcome document of the thirtieth special session of the General Assembly, on the world drug problem, held in 2016, Member States resolved to strengthen national and international action to address the emerging challenge of new psychoactive substances, including their adverse health consequences, and the evolving threat of amphetamine-type stimulants, including methamphetamine, and underscored the importance of enhancing information-sharing and early warning networks, developing appropriate national legislative, prevention and treatment models and supporting scientific evidence-based review and scheduling of the most prevalent, persistent and harmful substances.

In the Ministerial Declaration of 2019, Member States committed to continuing to facilitate informed scheduling decisions on the most persistent, prevalent and harmful substances, including synthetic drugs and new psychoactive substances, precursors, chemicals and solvents, while ensuring their availability for medical and scientific purposes.

In its resolution 66/3, entitled “Strengthening information-sharing to increase scientific evidence-based support for international scheduling and the effective implementation of international scheduling decisions”, the Commission expressed concern that synthetic drugs and the non-medical use of prescription drugs posed increasing risks to health and safety, as well as scientific, legal and regulatory challenges, including with regard to the scheduling of substances. The Commission acknowledged the efforts of INCB and WHO to bring to the attention of the Commission the challenges related to new psychoactive substances and new precursor

chemicals. In addition, the Commission welcomed cooperation between Member States, UNODC, INCB and other relevant international and regional organizations to implement proactive approaches to detect and identify new psychoactive substances and new precursor chemicals.

(c) International Narcotics Control Board

The annual report of INCB is submitted to the Economic and Social Council through the Commission, in accordance with the provisions of the international drug control treaties. The Commission may make such comments on the report as it sees fit. In addition, article 8 of the 1961 Convention as amended, article 17 of the 1971 Convention and article 21 of the 1988 Convention authorize the Commission to call the attention of the Board to any matters that may be relevant to the functions of the Board. The report of the Board for 2023 (E/INCB/2023/1) will be before the Commission.

Article 12, paragraph 13, of the 1988 Convention requires the Board to report annually to the Commission on the implementation of that article. It is suggested that the report of the Board for 2023 on the implementation of article 12 of the 1988 Convention (E/INCB/2023/4) be considered at the same time as the report of the Board for 2023 (E/INCB/2023/1), in line with past practice.

(d) International cooperation to ensure the availability of narcotic drugs and psychotropic substances for medical and scientific purposes while preventing their diversion

In the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem, adopted in 2009, Member States called for continued cooperation between Member States, INCB and WHO to ensure the adequate availability of narcotic drugs and psychotropic substances under international control, including opiates, for medical and scientific purposes, while concurrently preventing their diversion into illicit channels, pursuant to the international drug control conventions, and recommended a set of actions.

The outcome document of the thirtieth special session of the General Assembly, on the world drug problem, includes a stand-alone chapter with operational recommendations on ensuring the availability of, and access to, controlled substances exclusively for medical and scientific purposes, while preventing their diversion.

In the Ministerial Declaration of 2019, Member States noted with concern that the availability of internationally controlled substances for medical and scientific purposes remained low to non-existent in many parts of the world and reiterated their resolve to ensure access to, and the availability of, controlled substances for medical and scientific purposes, including for the relief of pain and suffering, and address existing barriers in that regard.

In its resolution 64/1, the Commission noted with concern the difficulties encountered by Member States in ensuring the continued access to and availability of internationally controlled substances for medical and scientific purposes throughout the world, and expressed its appreciation for the work of INCB and UNODC, within their respective mandates, in supporting Member States to ensure the access to and availability of such drugs, as well as in raising awareness about the problem. In addition, the Commission encouraged Member States to continue to address barriers to access to and availability of controlled substances for medical and scientific purposes, while preventing their non-medical use or diversion into illicit channels.

In its resolution 64/4, the Commission noted the concern expressed by INCB in its annual report for 2020 about reported shortages of medicines containing controlled substances such as fentanyl and midazolam in some countries, largely driven by significant increases in the need to provide pain relief and sedation for patients with the coronavirus disease (COVID-19) admitted into intensive care units, and that the Board had encouraged Governments to continue working closely with one another

and with the Board to ensure the global availability of medicines containing controlled substances, especially for those who were most in need during emergency situations.

During the regular part of the sixty-fifth session, the Chair of the Commission launched, in close cooperation with the Executive Director of UNODC, the Director General of WHO and the President of INCB, a global awareness-raising initiative with the motto #NoPatientLeftBehind, to scale up the implementation of the international drug policy commitments on improving the availability of and access to controlled substances for medical and scientific purposes. Further information on the initiative is available on the UNODC availability and access web page.⁶ Awareness-raising activities on the topic continued during the sixty-sixth session, with the participation of the Chairs of the sixty-fifth and sixty-sixth sessions and the Chair who had been nominated for the sixty-seventh session.

(e) Other matters arising from the international drug control treaties

The Commission will have before it the latest issue of the publication entitled *Competent National Authorities under the International Drug Control Treaties* (ST/NAR.3/2023/1), which provides information to facilitate cooperation between competent national authorities that are empowered to issue certificates and authorizations for the import and export of narcotic drugs and psychotropic substances and that regulate or enforce national controls over precursors and essential chemicals in accordance with the international drug control treaties.

The Commission will also have before it the latest issue of the publication entitled *Manufacture of Narcotic Drugs, Psychotropic Substances and Their Precursors: 2022* (ST/NAR.4/2022/1), which provides information on national manufacturers authorized by Governments to manufacture or convert specific narcotic drugs and psychotropic substances, as well as manufacturers of precursor chemicals.

Documentation

Note by the Secretariat on changes in the scope of control of substances: proposed scheduling recommendations by the World Health Organization (E/CN.7/2024/12)

Note by the Secretariat on the scope of control of substances under the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988: (a) P-2-P methyl glycidic acid (“BMK glycidic acid”) and its methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl and *tert*-butyl esters; and (b) the ethyl ester of 3,4-MDP-2-P methyl glycidic acid (“PMK ethyl glycidate”) and of six additional esters of 3,4-MDP-2-P methyl glycidic acid (E/CN.7/2024/13)

Note by the Secretariat on the scope of control of substances under the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988: 4-piperidone and 1-boc-4-piperidone (E/CN.7/2024/14)

Report of the International Narcotics Control Board for 2023 (E/INCB/2023/1)

Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2023 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2023/4)

Competent National Authorities under the International Drug Control Treaties (ST/NAR.3/2023/1)

Manufacture of Narcotic Drugs, Psychotropic Substances and Their Precursors: 2022 (ST/NAR.4/2022/1)

⁶ www.unodc.org/unodc/en/commissions/CND/session/65_Session_2022/availability_and_access.html.

6. Follow-up to the implementation at the national, regional and international levels of all commitments, as reflected in the Ministerial Declaration of 2019, to address and counter the world drug problem

The high-level segment to be held on 14 and 15 March 2024 will address the follow-up to the Ministerial Declaration of 2019, as explained under agenda item 3. The consideration of agenda item 6 will provide the first opportunity to discuss the follow-up to the Ministerial Declaration of 2019 after the high-level segment, as well as to discuss the implementation of the outcome that is expected to be adopted at the opening of the high-level segment.

Two thematic sessions were held by the Commission in a hybrid format: one from 23 to 25 October 2023, and one from 4 to 6 December 2023. In line with the multi-year workplan adopted by the Commission in June 2019, the thematic discussions undertook a comprehensive stocktaking of the progress made in implementing the international drug policy commitments to address all 11 challenges identified in the Ministerial Declaration, with half a day devoted to each challenge and the afternoon of the last day of the second session serving as a closing with a focus on the way forward. Each challenge was the subject of two introductory presentations by UNODC and an interactive debate. More information on the thematic discussions can be found on the UNODC website.⁷ The Chair's summary of the thematic discussions, which was not subject to negotiation, is available in the form of a conference room paper (E/CN.7/2024/CRP.1).

At its sixty-seventh session, the Commission will also have before it a conference room paper containing a note by the Secretariat on the implementation of all international drug policy commitments in follow-up to the Ministerial Declaration of 2019 (E/CN.7/2024/CRP.2).

In its resolution 53/16, the Commission requested the Executive Director of UNODC to continue to submit to it annual reports on trends in global drug abuse and the illicit supply of drugs, in accordance with the reporting mandates contained in the 1961 Convention as amended and the 1971 Convention. Furthermore, in its resolution 54/9, the Commission requested the Executive Director to provide an overview of measures and activities undertaken by UNODC to enhance the scientific quality of its reporting mechanisms and the support given to Member States in developing their capacity for data collection and analysis.

The report of the Secretariat on the world situation with regard to drug abuse is contained in document [E/CN.7/2024/6](#).

Furthermore, the Commission will have before it the report of the Secretariat on the world situation with regard to drug trafficking ([E/CN.7/2024/7](#)), which includes information on the implementation of resolution 53/16, as well as resolutions 54/9 and 56/5. The report provides an overview of the latest trends in illicit drug production and trafficking worldwide.

The "single-track" approach to which States committed in the Ministerial Declaration of 2019 entailed, inter alia, ensuring that the collection of reliable and comparable data, through a strengthened and streamlined annual report questionnaire, reflected all commitments. In the Ministerial Declaration, States requested the Executive Director of UNODC to adapt the existing biennial report, transforming it into a single report, to be prepared on a biennial basis, within existing resources, on the basis of the responses provided by Member States to the strengthened and streamlined annual report questionnaire on progress made to implement all commitments at the national, regional and international levels: the second such report will be submitted for consideration by the Commission at its sixty-seventh session. Accordingly, the Commission will have before it the report of the Executive Director on progress made in the implementation of all international drug policy commitments to address and

⁷ www.unodc.org/unodc/en/commissions/CND/session/66_Session_2023/thematic-sessions.html?testme.

counter the world drug problem, prepared on the basis of the new annual report questionnaire (E/CN.7/2024/8). An advanced version of the report was presented at the reconvened sixty-sixth session (E/CN.7/2023/CRP.18).

As requested in Commission resolution 49/4, entitled “Responding to the prevalence of HIV/AIDS and other blood-borne diseases among drug users”, and Commission resolution 60/8, entitled “Promoting measures to prevent HIV and other blood-borne diseases associated with the use of drugs, and increasing financing for the global HIV/AIDS response and for drug use prevention and other drug demand reduction measures”, the Commission will have before it the report of the Executive Director on responding to the prevalence of HIV/AIDS and other blood-borne diseases among drug users (E/CN.7/2024/9).

Pursuant to Commission resolution 56/3, the Commission will have before it a conference room paper containing the report of the Secretariat on strengthening international cooperation in combating illicit opiates originating in Afghanistan through continuous and reinforced support to the Paris Pact initiative (E/CN.7/2024/CRP.6).

Documentation

Report of the Executive Director on the activities of the United Nations Office on Drugs and Crime (E/CN.7/2024/2-E/CN.15/2024/2)

Report of the Secretariat on the world situation with regard to drug abuse (E/CN.7/2024/6)

Report of the Secretariat on the world situation with regard to drug trafficking (E/CN.7/2024/7)

Report of the Executive Director on progress made in the implementation of all international drug policy commitments to address and counter the world drug problem (E/CN.7/2024/8)

Report of the Executive Director on responding to the prevalence of HIV/AIDS and other blood-borne diseases among drug users (E/CN.7/2024/9)

Conference room paper containing the Chair’s summary on the thematic discussions on the implementation of all international drug policy commitments, following up to the Ministerial Declaration of 2019 (23–25 October and 4–6 December 2023) (E/CN.7/2024/CRP.1)

Conference room paper containing a note by the Secretariat on the implementation of all international drug policy commitments, following up to the Ministerial Declaration of 2019 (E/CN.7/2024/CRP.2)

Conference room paper containing the report of the Secretariat on strengthening international cooperation in combating illicit opiates originating in Afghanistan through continuous and reinforced support to the Paris Pact initiative (E/CN.7/2024/CRP.6)

7. Inter-agency cooperation and coordination of efforts in addressing and countering the world drug problem

In the Political Declaration and Plan of Action of 2009, Member States encouraged international and regional agencies working on drug demand and supply reduction, in particular UNODC, WHO, the United Nations Development Programme, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and INCB, to engage in dialogue in order to strengthen inter-agency cooperation for a more effective response, while respecting each organization’s role and mandate.

In the outcome document of the thirtieth special session of the General Assembly, on the world drug problem, Member States reaffirmed the principal role of the Commission as the policymaking body of the United Nations with prime responsibility for drug control matters, and reaffirmed their support and appreciation

for the efforts of UNODC as the leading entity in the United Nations system for addressing and countering the world drug problem. Also in the outcome document, Member States encouraged the Commission and UNODC to further increase cooperation and collaboration with all relevant United Nations entities and international financial institutions, within their respective mandates, when assisting Member States in designing and implementing comprehensive, integrated and balanced national drug strategies, policies and programmes.

In the Ministerial Declaration of 2019, Member States encouraged further contributions of relevant United Nations entities, international financial institutions and relevant regional and international organizations, within their respective mandates, to the work of the Commission and the efforts of Member States to address and counter the world drug problem, upon their request, to strengthen international and inter-agency cooperation, and encourage them to make available relevant information to the Commission in order to facilitate its work and to enhance coherence within the United Nations system at all levels with regard to the world drug problem.

The Commission also continues to actively seek to strengthen horizontal cooperation with the other functional commissions of the Economic and Social Council, addressing cross-cutting issues in the broader framework of the 2030 Agenda.

In its resolutions 71/211, 72/198, 73/192, 74/178, 75/198, 76/188 and 77/238, the General Assembly noted with appreciation the contributions of United Nations entities, international financial institutions and relevant regional and international organizations to the work of the Commission, to strengthen international and inter-agency cooperation.

During the internal meeting of the Chief Executives Board for Coordination held in November 2018, principals of the United Nations agencies discussed how the United Nations system could most effectively support the implementation of international drug control policy through effective inter-agency collaboration. At the meeting of the Board, principals adopted the common United Nations position on drug policy, in which they committed to strengthening inter-agency cooperation, making best use of the expertise within the United Nations system and supporting each other's activities, within established mandates, and to delivering balanced, comprehensive, integrated, evidence-based, human rights-based, development-oriented and sustainable support to Member States in implementing their joint commitments.

With a view to ensuring coherent efforts to realize the commitments under the common United Nations position on drug policy and, in particular, coordinated data collection to promote scientific, evidence-based implementation of international commitments, a United Nations system coordination task team, led by UNODC, was created within the framework of the Secretary-General's Executive Committee in preparation for the ministerial segment of the sixty-second session of the Commission.

In the Ministerial Declaration of 2019, Member States encouraged the relevant United Nations entities, the international financial institutions and relevant regional and international organizations, within their respective mandates, to further contribute to the work of the Commission.

In the follow-up to the Ministerial Declaration of 2019, the UNODC-led task team conducted a series of meetings to discuss how to focus its attention on strategic communication to United Nations resident coordinators and United Nations country teams to encourage a coordinated approach to the drug problem in line with the common position by supporting Member States in the implementation of international drug policy commitments through effective inter-agency collaboration. The task team also developed a joint document to serve as a guideline for the United Nations country teams to conduct a common country analysis and develop a United Nations Sustainable Development Cooperation Framework that encompasses drug matters.

The Commission will have before it a conference room paper prepared by the Secretariat on efforts undertaken together with relevant United Nations entities and

other stakeholders in supporting Member States with the implementation of their joint commitments (E/CN.7/2024/CRP.3). UNODC will further provide a briefing on the work of the United Nations system coordination task team during the consideration of this agenda item.

Pursuant to Commission resolution 51/14, relevant decisions of UNAIDS are transmitted to the Commission in a note by the Secretariat on promoting coordination and alignment of decisions between the Commission and the Programme Coordinating Board of UNAIDS. Information on the relevant decisions of the Board will be before the Commission in document [E/CN.7/2024/10](#). In its resolution 62/6, the Commission requested UNODC, as the convening agency of UNAIDS for matters relating to HIV/AIDS and drug use and to HIV/AIDS in prison settings, to continue to provide its leadership and guidance on those matters, in partnership with relevant United Nations entities.

Documentation

Note by the Secretariat on promoting coordination and alignment of decisions between the Commission on Narcotic Drugs and the Programme Coordinating Board of the Joint United Nations Programme on HIV/AIDS ([E/CN.7/2024/10](#))

Conference room paper prepared by the Secretariat on efforts undertaken together with relevant United Nations entities and other stakeholders in supporting Member States with the implementation of their joint commitments (E/CN.7/2024/CRP.3)

8. Recommendations of the subsidiary bodies of the Commission

In its resolutions 74/178, 75/198, 76/188 and 77/238, the General Assembly referred to the contribution of the meetings of heads of national drug law enforcement agencies and of the Subcommission on Illicit Drug Traffic and Related Matters in the Near and Middle East to the strengthening of regional and international cooperation. The Commission will be informed of the results of the meetings of its subsidiary bodies held since its sixty-sixth session.

The meetings of the Commission's subsidiary bodies were held in person. At the meetings, participants discussed the current situation with regard to regional and subregional cooperation in addressing and countering the world drug problem; the implementation of the recommendations adopted by the previous meeting; the follow-up on the implementation at the national, regional and international levels of all commitments, as reflected in the Ministerial Declaration of 2019, to address and counter the world drug problem, and preparations for the midterm review to be held in 2024; and the organization of the next meeting. Participants at the various meetings were also organized into working groups to consider the following topics: (a) regional and international cooperation to reduce illicit cultivation and production of drugs, including alternative development; (b) financial investigations in drug trafficking cases, and the role of cryptocurrencies in drug trafficking and related money-laundering; (c) measures to counter the illicit manufacturing and diversion of precursor chemicals; and (d) the link between drugs and the environment.

The Commission is invited to consider the recommendations made at the Fifteenth Meeting of Heads of National Drug Law Enforcement Agencies, Europe, held in Tirana from 20 to 23 June 2023; the Thirty-first Meeting of Heads of National Drug Law Enforcement Agencies, Africa, held in Abuja from 26 to 29 September 2023; the Thirty-first Meeting of Heads of National Drug Law Enforcement Agencies, Latin America and the Caribbean, held in Quito from 3 to 6 October 2023; the Forty-fifth Meeting of Heads of National Drug Law Enforcement Agencies, Asia and the Pacific, held in Kuta, Indonesia, from 24 to 27 October 2023; and the fifty-sixth session of the Subcommission on Illicit Drug Traffic and Related Matters in the Near and Middle East, held in Bishkek from 21 to 24 November 2023, with a view to taking any required follow-up action.

Pursuant to Commission resolution 56/10, a report of the Secretariat on action taken by the subsidiary bodies of the Commission has been prepared and is contained in document [E/CN.7/2024/11](#).

Documentation

Report of the Secretariat on action taken by the subsidiary bodies of the Commission on Narcotic Drugs ([E/CN.7/2024/11](#))

9. Contributions by the Commission to the work of the Economic and Social Council, in line with General Assembly resolutions 75/290 A and 75/290 B, including follow-up to and review and implementation of the 2030 Agenda for Sustainable Development

At its fifty-eighth session, in March 2015, the Commission decided to include a standing item on its agenda focusing on its contributions to the work of the Economic and Social Council, in line with General Assembly resolution 68/1. In accordance with that same resolution, the Commission has been contributing, as appropriate, to the work of the Council relating to the common themes of the annual framework of the Council.

In the outcome document of the thirtieth special session of the General Assembly, on the world drug problem, Member States welcomed the 2030 Agenda and noted that efforts to achieve the Sustainable Development Goals and to effectively address the world drug problem were complementary and mutually reinforcing. Also in the outcome document, Member States encouraged the Commission to contribute to the global follow-up and support the thematic review of progress on the Sustainable Development Goals, within its mandates, bearing in mind the integrated nature of the Goals as well as the interlinkages between them, and make that information available to the high-level political forum on sustainable development through the appropriate institutional framework, taking into account Assembly resolution 70/1.

In its resolution 72/305 on the review of the implementation of General Assembly resolution 68/1 on the strengthening of the Economic and Social Council, the Assembly requested the Council to improve its outcomes and the outcomes of its subsidiary bodies, making them more relevant, coherent and solution-oriented to address implementation challenges and ensuring their follow-up so as to strengthen the impact of the work of the Council.

In the Ministerial Declaration of 2019, Member States reiterated that efforts to achieve the Sustainable Development Goals and to effectively address the world drug problem were complementary and mutually reinforcing.

At its reconvened sixty-fourth session, the Commission considered a conference room paper containing information on the implementation of General Assembly resolution 75/290 A on the strengthening of the Economic and Social Council ([E/CN.7/2021/CRP.14-E/CN.15/2021/CRP.8](#)). The resolution established a new coordination segment, replacing the integration segment and the informal meeting of the Council with the Chairs of the subsidiary bodies. The coordination segment is intended to steer the Council system towards an efficient and integrated workflow, to provide guidance and coordination to subsidiary bodies, ensuring a clearer division of labour among them, and to develop action-oriented assessment and recommendations so that those bodies best contribute to the preparations for the thematic review of the high-level political forum. The 2024 coordination segment will be held on 31 January and 1 February 2024 at United Nations Headquarters.

In General Assembly resolution 75/290 A, the Economic and Social Council was invited to continue to strengthen its oversight, guidance and coordination role of its subsidiary bodies as outlined in paragraphs 28 and 29 of the annex to Assembly resolution 72/305. In addition, the President and Bureau of the Council were invited to work with the bureaux of its subsidiary bodies and in consultation with delegations during the 2022 session of the Council, so as to identify possible actions to be taken

to implement the provisions regarding enhancing the work of subsidiary bodies contained in paragraphs 28 and 29 of the annex to Assembly resolution 72/305.

The Commission took an active role in the review by the Economic and Social Council of its functional commissions and expert bodies mandated by General Assembly resolution 75/290 A, and submitted an assessment of its work to the Council in April 2022. In its decision 2022/334, the Council took note of the summary of the Vice-President of the Council on the review. The Council will review the implementation of the recommendations at its 2026 session. At its reconvened sixty-fifth session, the Commission considered a conference room paper by the Secretariat on the Council's review (E/CN.7/2022/CRP.17-E/CN.15/2022/CRP.10).

The high-level political forum on sustainable development will be convened under the auspices of the Economic and Social Council in New York from 8 to 18 July 2024. The thematic focus will be "Reinforcing the 2030 Agenda and eradicating poverty in times of multiple crises: the effective delivery of sustainable, resilient and innovative solutions". As in past years, the Commission will continue to provide substantive input to the high-level political forum.

The Commission may wish to use its sixty-seventh session to further consider how it can best contribute to the follow-up to, and support the implementation of, the 2030 Agenda, within its mandates, as well as how to further enhance synergies between its work and that of other functional commissions of the Economic and Social Council. The Commission may also wish to discuss its implementation of the recommendations stemming from the Council's review of its functional commissions and expert bodies mandated by General Assembly resolution 75/290 A.

10. Provisional agenda for the sixty-eighth session of the Commission

Under agenda item 10, the Commission should devote time to the consideration of any further enhancements that it may deem appropriate to the provisional agenda for its sixty-eighth and subsequent sessions.

11. Other business

No issues that need to be raised under item 11 have been brought to the attention of the Secretariat, and no documentation on the item is currently foreseen.

12. Adoption of the report of the Commission on its sixty-seventh session

It is expected that the Commission will adopt the report on its sixty-seventh session in the afternoon of 22 March 2024.

Annex

Proposed organization of work

1. In its resolution 1991/39, the Economic and Social Council decided that the Commission on Narcotic Drugs should establish a committee, the membership of which should be open to all States members of the Commission, to perform such functions as requested by the Commission in order to assist it in dealing with its agenda and to facilitate its work.
2. In accordance with established practice, the Commission will first consider draft resolutions in the Committee of the Whole before they are submitted to the plenary. Pursuant to Commission decision 55/1, the formal deadline for submission of draft resolutions to be considered at the sixty-seventh session is four weeks prior to the commencement of the session, that is, Thursday, 15 February 2024, at noon. States members of the Commission intending to submit draft resolutions for consideration by the Commission at its sixty-seventh session are requested to submit them to the Secretariat as early as possible and at the latest by the formal deadline.
3. The proposed organization of work is subject to approval by the Commission. As soon as discussion on an item or sub-item has been concluded, the following one will be taken up, time permitting. Suggested meeting times are from 10 a.m. to 1 p.m. and from 3 to 6 p.m.
4. The allotted speaking time of five minutes during the high-level segment, and three minutes during the regular segment, must be strictly adhered to during the sixty-seventh session.
5. As agreed at the reconvened sixty-sixth session, on 8 December 2023, upon the recommendation of the extended Bureau, the pre-session consultations on 13 March will be held in English only.

Informal pre-session consultations, 13 March 2024

Date and time

Wednesday, 13 March 2024

10 a.m.–1 p.m.	Informal consultations
3–6 p.m.	Informal consultations (<i>continued</i>)

Opening of the sixty-seventh session, 14 March 2024

<i>Date and time</i>	<i>Plenary</i>
----------------------	----------------

Thursday, 14 March 2024

9.30 a.m.	Opening of the sixty-seventh session of the Commission on Narcotic Drugs
	Item 1. Election of officers
	Item 2. Adoption of the agenda and other organizational matters

High-level segment, 14 and 15 March 2024

<i>Date and time</i>	<i>Plenary</i>
----------------------	----------------

<i>Round-table discussions</i>

Thursday, 14 March 2024

10 a.m. Item 3. High-level segment:

<i>Date and time</i>	<i>Plenary</i>	<i>Round-table discussions</i>
	(a) Opening of the high-level segment (including the adoption of the outcome document)	
	(b) General debate of the high-level segment	
3 p.m.	(b) General debate of the high-level segment (<i>continued</i>)	3 p.m. (c) Interactive, multi-stakeholder round table of the high-level segment: (i) Taking stock: work undertaken since 2019
7 p.m.	(b) General debate of the high-level segment (<i>continued</i>)	
Friday, 15 March 2024		
10 a.m.	(b) General debate of the high-level segment (<i>continued</i>)	10 a.m. (c) Interactive, multi-stakeholder round table of the high-level segment: (ii) The way forward: the road to 2029
3 p.m.	(b) General debate of the high-level segment (<i>continued</i>) (d) Closure of the high-level segment (including presentation of the co-chairs' summary of the salient points raised during the round tables)	

Regular part of the sixty-seventh session, 18–22 March 2024

<i>Date and time</i>	<i>Plenary</i>	<i>Committee of the Whole</i>
Monday, 18 March		
10 a.m.–1 p.m.	Item 2. Adoption of the agenda and other organizational matters (<i>continued</i>) Operational segment Item 4. Strategic management, budgetary and administrative questions: (a) Work of the standing open-ended intergovernmental working group on improving the governance and financial situation of the United Nations Office on Drugs and Crime; (b) Directives on policy and budgetary issues for the drug programme of the United Nations Office on Drugs and Crime; (c) Working methods of the Commission; (d) Staff composition of the United Nations Office on Drugs and Crime and other related matters	
3–6 p.m.	Item 4. Strategic management, budgetary and administrative questions (<i>continued</i>)	Consideration of draft resolutions

Date and time	Plenary	Committee of the Whole
Tuesday, 19 March		
10 a.m.–1 p.m.	Normative segment Item 5. Implementation of the international drug control treaties: (a) Changes in the scope of control of substances (b) Challenges and future work of the Commission on Narcotic Drugs and the World Health Organization in the review of substances for possible scheduling recommendations (c) International Narcotics Control Board; (d) International cooperation to ensure the availability of narcotic drugs and psychotropic substances for medical and scientific purposes while preventing their diversion (e) Other matters arising from the international drug control treaties	
3–6 p.m.	Item 5. Implementation of the international drug control treaties (<i>continued</i>)	Consideration of draft resolutions (<i>continued</i>)
Wednesday, 20 March		
10 a.m.–1 p.m.	Item 6. Follow-up to the implementation at the national, regional and international levels of all commitments, as reflected in the Ministerial Declaration of 2019, to address and counter the world drug problem	Consideration of draft resolutions (<i>continued</i>)
3–6 p.m.	Item 6. Follow-up to the implementation at the national, regional and international levels of all commitments, as reflected in the Ministerial Declaration of 2019, to address and counter the world drug problem (<i>continued</i>)	Consideration of draft resolutions (<i>continued</i>)
Thursday, 21 March		
10 a.m.–1 p.m.	Item 7. Inter-agency cooperation and coordination of efforts in addressing and countering the world drug problem	Consideration of draft resolutions (<i>continued</i>)
3–6 p.m.	Item 8. Recommendations of the subsidiary bodies of the commission Item 9. Contributions by the Commission to the work of the Economic and Social Council, in line with General Assembly resolutions 75/290 A and 75/290 B, including follow-up to and review and implementation of the 2030 Agenda for Sustainable Development	Consideration of draft resolutions (<i>continued</i>)
Friday, 22 March		
10 a.m.–1 p.m.	Item 10. Provisional agenda for the sixty-eighth session of the Commission	Consideration of draft resolutions (<i>continued</i>)
3–6 p.m.	Item 11. Other business Item 12. Adoption of the report of the Commission on its sixty-seventh session	